Exchange Traded Concepts LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,517 shares of the company’s stock after buying an additional 1,226 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Johnson & Johnson were worth $10,343,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. International Assets Investment Management LLC increased its position in shares of Johnson & Johnson by 20,130.0% in the 3rd quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock worth $559,832,000 after purchasing an additional 3,437,397 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Johnson & Johnson by 228.1% in the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after buying an additional 2,356,359 shares during the last quarter. Franklin Resources Inc. raised its stake in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after buying an additional 1,729,281 shares in the last quarter. Holocene Advisors LP acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $225,040,000. Finally, FMR LLC increased its holdings in shares of Johnson & Johnson by 7.4% in the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company’s stock valued at $2,968,440,000 after acquiring an additional 1,265,748 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.
Insider Activity at Johnson & Johnson
In related news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.
Analyst Upgrades and Downgrades
Johnson & Johnson Trading Up 4.1 %
Johnson & Johnson stock opened at $152.91 on Tuesday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock has a market capitalization of $368.15 billion, a PE ratio of 22.99, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. The firm has a 50 day simple moving average of $147.85 and a 200-day simple moving average of $156.10. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. During the same quarter in the previous year, the business earned $2.29 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 10.56 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Find and Profitably Trade Stocks at 52-Week Lows
- Sizing Up a New Opportunity for NVIDIA Investors
- Why Invest in High-Yield Dividend Stocks?
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Investing In Preferred Stock vs. Common Stock
- The 3 Biggest M&A Stock Opportunities for 2025
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.